Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9.

Skrombolas D, Sullivan M, Frelinger JG.

J Interferon Cytokine Res. 2019 Apr;39(4):233-245. doi: 10.1089/jir.2018.0129. Epub 2019 Mar 8.

PMID:
30848689
2.

Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy.

Mikucki ME, Skitzki JJ, Frelinger JG, Odunsi K, Gajewski TF, Luster AD, Evans SS.

Oncoimmunology. 2016 Feb 11;5(5):e1116675. doi: 10.1080/2162402X.2015.1116675. eCollection 2016 May.

3.

Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints.

Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, Ku AW, Frelinger JG, Odunsi K, Gajewski TF, Luster AD, Evans SS.

Nat Commun. 2015 Jun 25;6:7458. doi: 10.1038/ncomms8458.

4.

Characterization of an IL-12 p40/p35 Truncated Fusion Protein That can Inhibit the Action of IL-12.

Skrombolas D, Wylie I, Maharaj S, Frelinger JG.

J Interferon Cytokine Res. 2015 Sep;35(9):690-7. doi: 10.1089/jir.2014.0176. Epub 2015 May 4.

5.

Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.

Skrombolas D, Frelinger JG.

Expert Rev Clin Immunol. 2014 Feb;10(2):207-17. doi: 10.1586/1744666X.2014.875856. Review.

6.

Generation of a dual-functioning antitumor immune response in the peritoneal cavity.

Sedlacek AL, Gerber SA, Randall TD, van Rooijen N, Frelinger JG, Lord EM.

Am J Pathol. 2013 Oct;183(4):1318-1328. doi: 10.1016/j.ajpath.2013.06.030. Epub 2013 Aug 8.

7.

Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model.

Yokota SJ, Facciponte JG, Kelleher RJ Jr, Shultz LD, Loyall JL, Parsons RR, Odunsi K, Frelinger JG, Lord EM, Gerber SA, Balu-Iyer SV, Bankert RB.

Cancer Immun. 2013 May 31;13:11. Print 2013.

8.

IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor.

Gerber SA, Sedlacek AL, Cron KR, Murphy SP, Frelinger JG, Lord EM.

Am J Pathol. 2013 Jun;182(6):2345-54. doi: 10.1016/j.ajpath.2013.02.041. Epub 2013 Apr 12.

9.

Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy.

Gerber SA, Sorensen EW, Sedlacek AL, Lim JY, Skrombolas D, Frelinger JG, Lord EM.

Immunology. 2013 Mar;138(3):280-92. doi: 10.1111/imm.12037.

10.

A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens.

Valentino MD, Abdul-Alim CS, Maben ZJ, Skrombolas D, Hensley LL, Kawula TH, Dziejman M, Lord EM, Frelinger JA, Frelinger JG.

J Immunol Methods. 2011 Oct 28;373(1-2):111-26. doi: 10.1016/j.jim.2011.08.007. Epub 2011 Aug 18.

11.

Identification of T-cell epitopes in Francisella tularensis using an ordered protein array of serological targets.

Valentino MD, Maben ZJ, Hensley LL, Woolard MD, Kawula TH, Frelinger JA, Frelinger JG.

Immunology. 2011 Mar;132(3):348-60. doi: 10.1111/j.1365-2567.2010.03387.x. Epub 2011 Jan 7.

12.

IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms.

Sorensen EW, Gerber SA, Frelinger JG, Lord EM.

J Immunol. 2010 Feb 15;184(4):1858-66. doi: 10.4049/jimmunol.0903210. Epub 2010 Jan 8.

13.

Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS.

Valentino MD, Hensley LL, Skrombolas D, McPherson PL, Woolard MD, Kawula TH, Frelinger JA, Frelinger JG.

Mol Immunol. 2009 May;46(8-9):1830-8. doi: 10.1016/j.molimm.2009.01.008. Epub 2009 Feb 23.

14.

Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity.

Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM.

J Immunol. 2008 Mar 1;180(5):3132-9.

15.

Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: implications for their use as immunization vectors.

Santos K, Simon DA, Conway E, Bowers WJ, Mitra S, Foster TH, Lugade A, Lord EM, Federoff HJ, Dewhurst S, Frelinger JG.

Hum Gene Ther. 2007 Feb;18(2):93-105.

PMID:
17298238
16.

Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo.

Malboeuf CM, Simon DA, Lee YE, Lankes HA, Dewhurst S, Frelinger JG, Rose RC.

Vaccine. 2007 Apr 30;25(17):3270-6. Epub 2007 Jan 22.

PMID:
17293010
17.

In vivo study of T-cell responses to skin alloantigens in Xenopus using a novel whole-mount immunohistology method.

Ramanayake T, Simon DA, Frelinger JG, Lord EM, Robert J.

Transplantation. 2007 Jan 27;83(2):159-66.

PMID:
17264812
18.

Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1alpha.

Mitra S, Cassar SE, Niles DJ, Puskas JA, Frelinger JG, Foster TH.

Mol Cancer Ther. 2006 Dec;5(12):3268-74.

19.

Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag.

Santos K, Duke CM, Rodriguez-Colon SM, Dakwar A, Fan S, Keefer MC, Federoff HJ, Frelinger JG, Bowers WJ, Dewhurst S.

Vaccine. 2007 Feb 19;25(9):1634-46. Epub 2006 Nov 15.

20.
21.

Quorum sensing: dynamic response of Pseudomonas aeruginosa to external signals.

Wagner VE, Frelinger JG, Barth RK, Iglewski BH.

Trends Microbiol. 2006 Feb;14(2):55-8. Epub 2006 Jan 6.

PMID:
16406629
22.

Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.

Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM.

J Immunol. 2005 Jun 15;174(12):7516-23.

23.

Characterization of a lymph node within the mouse prostate: Detailed analysis using whole mount histology.

Gerber SA, Turner MJ, Lugade AA, Moran JP, Frelinger JG, Lord EM.

Prostate. 2005 May 1;63(2):105-16.

PMID:
15468173
24.

Imaging enzyme activity with polarization-sensitive confocal fluorescence microscopy.

Bigelow CE, Vishwasrao HD, Frelinger JG, Foster TH.

J Microsc. 2004 Jul;215(Pt 1):24-33.

25.
26.
27.

Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts.

Gerber SA, Moran JP, Frelinger JG, Frelinger JA, Fenton BM, Lord EM.

Br J Cancer. 2003 May 6;88(9):1453-61.

28.

Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors.

Fisher TL, Nocera M, Willis RA, Turner MJ, Abdul Alim CS, Brown DM, Bourne PA, di Sant'Agnese PA, Messing EM, Lord EM, Frelinger JG.

Prostate. 2002 May 15;51(3):153-65.

PMID:
11967950
29.

Epitope mapping of human herpesvirus-7 gp65 using monoclonal antibodies.

Skrincosky D, Willis RA, Hocknell PK, Frelinger JG, Mirandola P, Wang X, Dewhurst S.

Arch Virol. 2001;146(9):1705-22.

PMID:
11699957
30.

Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice.

Willis RA, Bowers WJ, Turner MJ, Fisher TL, Abdul-Alim CS, Howard DF, Federoff HJ, Lord EM, Frelinger JG.

Hum Gene Ther. 2001 Oct 10;12(15):1867-79.

PMID:
11589829
31.

T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopes.

Turner MJ, Abdul-Alim CS, Willis RA, Fisher TL, Lord EM, Frelinger JG.

J Immunol Methods. 2001 Oct 1;256(1-2):107-19.

PMID:
11516759
32.

Tumours can act as adjuvants for humoral immunity.

Brown DM, Fisher TL, Wei C, Frelinger JG, Lord EM.

Immunology. 2001 Apr;102(4):486-97.

33.
34.

Alteration of tumour response to radiation by interleukin-2 gene transfer.

Lee J, Moran JP, Fenton BM, Koch CJ, Frelinger JG, Keng PC, Lord EM.

Br J Cancer. 2000 Feb;82(4):937-44.

35.

Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum.

Conway TF Jr, Sabel MS, Sugano M, Frelinger JG, Egilmez NK, Chen F, Bankert RB.

J Immunol Methods. 2000 Jan 13;233(1-2):57-65.

PMID:
10648856
36.
37.
38.

The Roman god Janus: a paradigm for the function of CD43.

Ostberg JR, Barth RK, Frelinger JG.

Immunol Today. 1998 Dec;19(12):546-50. Review. No abstract available.

PMID:
9864944
39.

Regulation of human prostate-specific antigen gene expression in transgenic mice: evidence for an enhancer between the PSA and human glandular kallikrein-1 genes.

Wei C, Callahan BP, Turner MJ, Willis RA, Lord EM, Barth RK, Frelinger JG.

Int J Mol Med. 1998 Oct;2(4):487-96.

PMID:
9857240
40.

A transgenic strategy for analyzing the regulatory regions of the human prostate-specific antigen gene: potential applications for the treatment of prostate cancer (Review).

Willis RA, Wei C, Turner MJ, Callahan BP, Pugh AE, Barth RK, Lord EM, Frelinger JG.

Int J Mol Med. 1998 Feb;1(2):379-86. Review.

PMID:
9852240
42.

IL-3-mediated enhancement of particulate antigen presentation by macrophages.

Lord EM, Yeh KY, Moran JA, Storozynsky E, Frelinger JG.

J Immunother. 1998 May;21(3):205-10.

PMID:
9610912
43.

Tumor immunotherapy: cytokines and antigen presentation.

Lord EM, Frelinger JG.

Cancer Immunol Immunother. 1998 Apr;46(2):75-81. Review.

PMID:
9558002
44.

Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment.

Lee J, Fenton BM, Koch CJ, Frelinger JG, Lord EM.

Cancer Res. 1998 Apr 1;58(7):1478-85.

45.

Expression of mouse CD43 in the B cell lineage of transgenic mice causes impaired immune responses to T-independent antigens.

Ostberg JR, Dragone LL, Borrello MA, Phipps RP, Barth RK, Frelinger JG.

Eur J Immunol. 1997 Sep;27(9):2152-9.

PMID:
9341753
46.

Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy.

Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK, Frelinger JG.

Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6369-74.

47.

Anti-CD43 inhibition of T cell homing.

McEvoy LM, Sun H, Frelinger JG, Butcher EC.

J Exp Med. 1997 Apr 21;185(8):1493-8.

48.

Disregulated expression of CD43 (leukosialin, sialophorin) in the B cell lineage leads to immunodeficiency.

Ostberg JR, Dragone LL, Driskell T, Moynihan JA, Phipps R, Barth RK, Frelinger JG.

J Immunol. 1996 Dec 1;157(11):4876-84.

PMID:
8943391
49.

Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes.

Wei C, Storozynsky E, McAdam AJ, Yeh KY, Tilton BR, Willis RA, Barth RK, Looney RJ, Lord EM, Frelinger JG.

Cancer Immunol Immunother. 1996 Jul;42(6):362-8.

PMID:
8830740
50.

Supplemental Content

Loading ...
Support Center